Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases - PROJECT SUMMARY The repair and regeneration of diseased lungs using stem cells and bioengineered tissues represent exciting therapeutic frontiers for treating various lung diseases and critical illnesses. Over the past decade, preclinical models have provided growing evidence that non-resident lung cells can modulate immune responses following injury. However, translating these findings into clinical applications has remained challenging. Concurrently, bioengineering research has advanced, exploring artificial and acellular lung scaffolds for three-dimensional lung or airway regeneration. Recent breakthroughs include evidence for successful engraftment in transplantation attempts in large animal models, highlighting the synergy between bioengineering and stem cell-derived therapies. This dynamic field has also benefited from significant progress in understanding the molecular and cellular mechanisms underlying lung development, repair, and remodeling. Advances in characterizing endogenous lung stem and progenitor cells have further enriched our understanding of tissue regeneration. Since its inception in 2005, our biennial conference, open to all populations, held at the University of Vermont, has been a cornerstone of this rapidly evolving field. The 2025 meeting marks the 20th anniversary of this prestigious event, celebrating two decades of fostering collaboration, innovation, and discovery in stem cell, cell therapy, and lung bioengineering research. Modeled after the Gordon Conferences, this meeting uniquely provides a comprehensive platform for discussion, bridging cutting-edge science with clinical application. A hallmark of the conference’s success has been the promotion of trainees and junior investigators alongside prominent keynote speakers from both lung biology and broader stem cell disciplines. This feature will continue to define the 2025 conference as it builds on its legacy of shaping the field’s trajectory. Junior investigators, trainees, and researchers are prioritized for oral presentations, session chair roles, and poster discussions. Travel awards for trainees, determined through a rigorous blinded abstract review process, will be expanded to encourage broader participation. Planned for July 2025, this milestone conference will bring together leading scientists, representatives from key organizations such as the NHLBI, NSF, FDA, and non-profit respiratory foundations. Attendees will discuss the latest challenges and opportunities in stem cell therapies, bioengineering, and lung biology. The outcomes will help shape guidelines for basic, translational, and clinical research, benefiting investigators and funding agencies alike. As we celebrate two decades of transformative research and collaboration, this conference promises to continue its legacy of advancing the science and application of stem cells and bioengineering for lung disease. These conferences have resulted in a series of guidelines for basic, translational, and clinical research to be utilized by both investigators and funding agencies and are a testament to the power of community, innovation, and shared commitment to improving human health.
